Consistent with our previous in vitro results, the overexpression of NXPH4 significantly abolished the inhibitory effects of GEM treatment in parental bladder cancer cell-derived groups, as indicated by the increased tumor size and tumor weight (Figure 9A). The gene discussed is NXPH4; the disease is urinary bladder cancer.